A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph node transfer for the treatment of patients with secondary lymphedema associated with the treatment of breast cancer

Trial Profile

A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph node transfer for the treatment of patients with secondary lymphedema associated with the treatment of breast cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs AdVEGF-Herantis (Primary)
  • Indications Lymphoedema
  • Focus Therapeutic Use
  • Acronyms AdeLE
  • Sponsors Herantis Pharma
  • Most Recent Events

    • 13 Jun 2018 According to an Herantis Pharma media release, Anne Saarikko, MD, PhD, is the Principal Investigator of the study. By the end of 2018, 2-3 additional hospitals in Sweden and Finland are planned to start enrolling patients.
    • 18 May 2018 Status changed from planning to recruiting.
    • 08 Feb 2018 According to a Herantis Pharma media release, clinical trial application for this trial has been submitted to the regulatory authorities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top